title: Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
abstract: Predictors of recurrent cytomegalovirus (CMV) disease after the first episode of successfully treated CMV disease in orthotopic liver transplant recipients were studied. Recurrent CMV disease was defined as disease diagnosed > 14 days after the end of a minimum 8-day course of ganciclovir therapy for the first episode and was classified as early or late if it occurred within or after 90 days, respectively, after completion of ganciclovir treatment. Eleven (27%) of 41 patients had recurrent CMV disease (nine early recurrences and two late recurrences). Death was more likely to occur in patients with recurrent CMV disease than in those without it (55% vs. 13%, respectively; P = .006). Initial episodes of multiorgan CMV disease (P = .001) and CMV pneumonia (P = .012) were associated with early recurrence. Multivariate analysis showed that multiorgan CMV disease was independently associated with early recurrence (P = .003; odds ratio, 13.5; 95% confidence interval, 2.4-76.8). Recognition of risk factors for recurrent CMV disease may help identify patients for whom a more intensive therapeutic or diagnostic approach is needed.
authors.affiliation: Department of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Falagas
authors.forename: D R
authors.initials: DR
authors.lastname: Snydman
authors.forename: J
authors.initials: J
authors.lastname: Griffith
authors.forename: B G
authors.initials: BG
authors.lastname: Werner
authors.forename: R
authors.initials: R
authors.lastname: Freeman
authors.forename: R
authors.initials: R
authors.lastname: Rohrer
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000472:pathogenicity; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D006525:Hepatitis, Viral, Human / Q000175:diagnosis; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D009026:Mortality; D015999:Multivariate Analysis; D011024:Pneumonia, Viral / Q000175:diagnosis; D012008:Recurrence; D012307:Risk Factors; D014019:Tissue Donors
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir